By B.C. Hakkert, T.W. Kuijpers Pretreatment of endothelial cells with cytokines enhances the adherence of leukocytes, a process that is mediated by surface proteins expressed on both cell types. A threedimensional model system for the simultaneous determination of leukocyte adherence and migration was used to study the contribution of C D l l /CD18, endothelial leukocyteadhesion molecule-1 (ELAM-1) and VLA-4 in neutrophil and monocyte adherence to and migration through cytokineactivated endothelial cells. Pretreatment of endothelial cells for 4 hours with recombinant interleukin-1s (rlL-1s) was found to enhance neutrophil adherence and migration to a much greater extent than monocyte adherence and migration. Neutrophil adherence was almost completely prevented by the combined use of monoclonal antibodies (Mo-Abs) against ELAM-l and CD18. Although ELAM-l has been designated an endothelial cell-specific cytokine-inducible receptor for neutrophils, we observed that ENAZ, an anti-
S AN INITIAL EVENT in inflammation, neutrophils
A adhere to the vascular lining and migrate into the inflamed tissue, followed by monocytes.' Clinical and experimental evidence has shown the importance of the CD11/CD18 proteins on leukocytes in these processes. 24 To date, two ligands for LFA-1 (CDlla) have been identified: intercellular adhesion molecule-1 (ICAM-1) (CD54) and ICAM-2.5s6 These molecules are expressed on several cell types, including endothelial cells. The expression of ICAM-1 on endothelial cells is enhanced by the action of cytokines. 6 The adherence of leukocytes to cytokineactivated endothelial cells, however, is only mediated in part by CD18-dependent mechanisms.
Cytokines induce the expression of at least two other endothelial cell-specific adhesive proteins: endothelial leukocyte-adhesion molecule-1 (ELAM-l)7 and VCAM-1 or INCAM-1 ELAM-1 is an endothelial cell-specific molecule, absent on unstimulated endothelial cells but rapidly induced by cytokine stimulation, in a transient fa~hion.~"~*" The expression of VCAM-1 resembles that of ICAM-1, to which it is structurally related, in the sense that cytokine stimulation can induce its expression to a considerable extent. Like ELAM-1, its expression on resting endothelial cells is extremely low? VCAM-1 functions as the ligand for the integrin VLA-4 (CD49d/CD29),I2 which is expressed on resting lymphocytes, monocytes, and several other cells, but not on ne~trophi1s.l~ Although the role of ELAM-1 in cytokine-mediated neutrophil adherence has been e~t a b l i s h e d ,~~'~~'~~'~ it is still unclear whether ELAM-1 is also involved in cytokineinduced neutrophil migration. Similarly, VCAM-1 /VLAd was shown to contribute to lymphocyte and (to a lesser extent) to monocyte adherence to endothelial cell^.'^^'^ Involvement of VCAM-1 in leukocyte migration across cytokine-activated endothelial cells has been ~uggested,'~~'~ but not yet thoroughly investigated.
In this report we describe the contribution of the abovementioned adhesion molecules in neutrophil and monocyte ELAM-1 MoAb, significantly reduced monocyte adherence about 30%. MoAbs against VLA-4, the ligand of the cytokineinducible receptor VCAM-1, did not affect monocyte adherence. However, the combined use of the MoAbs against CD18, ELAM-1, and VLA-4 had a very strong and additive inhibitory effect on rlL-lwnduced monocyte adherence. The anti-CD18 MoAb reduced both rlL-lpinduced neutrophil and monocyte migration far below the level of the unstimulated controls, whereas neither the anti-ELAM-1 nor the anti-VIA-4 MoAb significantly affected the process of migration.
Our results indicate that neutrophils and monocytes initially adhere to cytokine-activated endothelial cells by CD18independent and (to a lesser extent) by CD18-dependent mechanisms and subsequently change gears to a completely CD18-dependent migratory mechanism. o 1991 by The American Society of Hematology. adherence and migration. For this purpose we used a three-dimensional model system consisting of endothelial cells cultured on a permeable collagen matrix, which allows simultaneous analysis of leukocyte adherence and migration:
MATERIALS AND METHODS
Endothelial cells were isolated from human umbilical cord veins according to Jaffe et al," with some minor modifications." Endothelial cells were cultured in a medium consisting of an equal mixture of RPMI 1640 and M199 (GIBCO, Paisly, UK), 20% (vol/vol) heat-inactivated human serum, 2 mmol/L glutamine (Merck, Darmstadt, Germany), penicillin (100 U/mL), streptomycin (100 U/mL), and fungizone (2.5 pg/mL) (GIBCO). Confluent endothelial cell monolayers (either first or second passage) were harvested by trypsin/EDTA (GIBCO) and subcultured on collagen matrices.
In the present study, the collagen matrices were prepared from bovine collagen (3 mg/mL, L l L L HAKKERT ET AL the previously used calf skin collagen (type I, Sigma Chemical Co, St Louis, MO). 4 The collagen solution (0.25 mL), consisting of eight parts of bovine collagen, one part 1OX phosphate-buffered saline (PBS), and one part 0.1 N NaOH, was allowed to form a gel at 37°C for 60 minutes in 48-well microtiter plates (Costar, Cambridge, MA). The gels were incubated overnight with culture medium and subsequently treated with human fibronectin (Fn; 10 kg/mL) for 30 minutes. The excess of Fn was removed by two washes with culture medium. Endothelial cells (4 x 1O4icmz) were seeded on top of the gel and grown to confluence. Confluency was determined by May-Griinwald/Giemsa staining.
Blood was obtained from healthy volunteers. Monocytes and neutrophils were purified from but@ coats of 500 mL of blood anticoagulated with 0.4% (wt/vol) trisodium citrate (pH 7.4) as described.2o In short, blood cells were centrifuged over isotonic Percoll (specific gravity at room temperature, 1.077/cm3). The interphase, containing the mononuclear cells, was taken for isolation of the monocytes by countercurrent centrifugal elutriation." Neutrophils were isolated from the pellet fraction of the Percoll gradient.'" Purified leukocytes (1 x 107/mL) were resuspended in labeling medium (RPMI 1640/M199,0.1% human albumin [HA]). Monocytes and neutrophils were greater than 95% pure, and viability was more than 95%, as determined by lactate dehydrogenase (LDH) r e l e a~e .~
The Immunofluorescence pow cyfometry. To investigate whether the nature of the culture substrate influences the ELAM-1, VCAM-1, and ICAM-1 expression by endothelial cells, indirect immunofluorescence flow cytometry analysis was performed. In short, endothelial cells were cultured on either collagen matrices or fibronectin in 6-well culture dishes. After the endothelial cells had reached confluency, the monolayers were incubated with recombinant interleukin-lp (rIL-1p) (10 U/mL, a gift from Dr P.T. Lomedico, Hoffmann-La Roche, Nutley, NJ) or culture medium (control) for 4 or 24 hours. Thereafter, the endothelial cells were shortly washed with PBS and nonenzymatically detached (1.5 mmol/L EDTA, 20 to 30 minutes). Primary MoAbs were added to the endothelial cell suspension, incubated for 30 minutes at 4°C and subsequently washed twice with ice-cold PBS, containing 0.5% (volivol) bovine serum albumin (BSA) and 7.5 mmol/L sodium azide. Thereafter, fluoresceinated goat-antimouse-Ig was added and left with the cells for another 30 minutes at 4°C. After two washes, MoAb binding was quantitated for 10,000 cells with a FACScan (Becton Dickinson, Mountain View, CA) and was expressed as mean fluorescence intensity (MFI).
The adhesionimigration assay was performed as de~cribed.~ Briefly, leukocytes were labeled with 5 1~2 4 and resuspended (1.2 x 106/mL) in incubation medium (RPMI 1649/M199, 0.5% HA). Endothelial cell monolayers pretreated for 4 hours with rIL-1p (10 U/mL) or culture medium Leukocytes.
Monoclonal antibodies (MoAbs).
Adhesion/migration assay.
(control) were washed twice with incubation medium. MoAbcontaining incubation medium (0.125 mL) was added to the endothelial cells. Radiolabeled leukocytes (2 x 105/mL; ie, five leukocytes per endothelial cell) were added to the endothelial cells. Culture plates were gently agitated for 1 minute and incubated for 20 minutes at 37T, 5% CO,. All incubations were run in quadruplicate. After incubation, the medium with unattached cells was collected, and the endothelial monolayers were washed twice with 0.25 mL of warm (37") incubation medium. These fractions were pooled (lumenal medium). The complete and intact endothelial cell monolayer together with the adhering leukocytes was harvested by incubation with 0.1 mL of collagenase (100 UimL; Worthington Bioch Corp, Freehold, NJ) for 5 to 10 minutes at 37°C (endothelial cell fraction). The collagenaseinduced detachment of the endothelial cell monolayers was followed by light microscopy. After the removal of the intact endothelial cell monolayers, the subendothelial matrices were carefully checked for remaining endothelial cells by microscopy. This method requires very tight endothelial cell monolayers, because the slightest gap or disruption inevitably results in the formation of several small endothelial cell fragments. After the harvesting of the intact endothelial cell monolayers, the collagen matrices were digested by collagenase (100 U/mL, 2 hours, 37"C), incubated with 0.2 mL of 1% (wtivol) Triton X-100 (30 minutes), and collected (subendothelium fraction). Radioactivity was measured in the three fractions. The recovexy of radioactivity was more than 92%. In this assay, leukocyte adherence and migration is defined as previously de~cribed,~ ie, leukocytes that stick to the endothelium are defined as adhering leukocytes and those that are located in the collagen matrix as migrated leukocytes. Percentages adherence and migration were calculated as follows: cpm in the endothelial cell fraction (adherence) or in the subendothelium fraction (migration)/total cpm added x 100%.
For statistical analysis paired Student's t-tests with Bonferroni adaptation were used. P values exceeding .05 were not considered significant.
Statistical analysis.

RESULTS
Effect of growth substrate on ELAM-1, VCAM-1, and ICAM-1 expression by endothelial cells.
The extent and the kinetics of ELAM-1, VCAM-1, and ICAM-1 expression by endothelial cells grown on either collagen matrices or fibronectin were essentially identical ( Table 1) . ELAM-1 and VCAM-1 were not expressed by resting endothelial cells. ELAM-1 expression was strongly induced by cytokine treatment of endothelial cells, reaching a maximum 4 hours after induction. rIL-lp-treatment of endothelial cells for 4 hours also induced the expression of VCAM-1 on endothelial cells. Unlike ELAM-1 and VCAM-1, ICAM-1 was already expressed by resting endothelial cells. Cytokineactivation of endothelial cells markedly enhanced the expression of ICAM-1, which did not decline within 24 hours.
Effects of MoAbs against CDl8, ELAM-1, and W -4 on
rIL-1 mnduced neutrophil adherence and migration. The pretreatment of endothelial cells for 4 hours with rIL-lp dramatically enhanced both neutrophil adherence and migration (165% & 13% and 210% ~f: 17%, mean ~f: SEM, respectively) (Fig 1) . The adherence of neutrophils to 4-hour rTL-lp-stimulated endothelial cells was only partly inhibited (29% f 4%; P < .05) by the antLCD18 MoAb CLB-LFA-1/1 (Fig 1) . In 
Fig 2. Effects of MoAbs against CDl8 (CLB-LFA-1/1), ELAM-1 (ENM), and VLA-4 (HP1/3) on rlL-lp-induced monocyte adherence and migration. Unstimulated endothelial cells (control; rlL-lp-pretreated endothelial cells (0). Bars represent percentage of monocyte adherence (bars at the top) and migration (bars at the bottom). For further experimental details see Materials and Methods.
Values are means f SEM of six independent experiments. (*) P < .05 and ( * * ) P < .01.
anti-ELAM-1 MoAb ENA2 (decrease, 55% f 5%; P < .01). However, the anti-ELAM-1 MoAb was much less effective than the CD18 MoAb in blocking neutrophil migration across monolayers of rIL-1 @-pretreated endothelial cells (inhibition, 28% k 6%; NS; and 65% f 3%; P < .01; respectively). The anti-ELAM-1 MoAb had no effect on neutrophil adherence to untreated or 24-hour rIL-1P-treated endothelial cells (data not shown). When the anti-ELAM-1 MoAb was used in combination with the anti-CD18 MoAb, an additive inhibitory effect was observed, resulting in a reduction of the rIL-lp-induced neutrophil adherence and migration below baseline levels.
The anti-VLA-4 MoAbs HP1/3 and HP2/1, either used alone or in combination with CD18 and ELAM-1 antibodies, had no effect on neutrophil adherence to or migration across cytokine-activated endothelial cells (data not shown). This finding is in line with the observation that VLA-4 is absent on neutrophils, as investigated with FACS analysis.
Effects of MoAbs against CD18, ELAM-1, and W -4 -a on rIL-1 P-induced monocyte adherence and migration.
Pretreatment of endothelial cells for 4 hours with rIL-lP also enhanced monocyte adherence and migration (38% f 5% and 94% f lo%, respectively; Fig 2) , although to a lesser extent than observed for neutrophils. The adherence of monocytes to rIL-1P-pretreated endothelial cells was only partly blocked (28% f 4%; P < .05) by the anti-CD18 MoAb (Fig 2) . In contrast, the anti-CD18 MoAb markedly reduced (51% f 4%; P < .01) monocyte migration across monolayers of cytokine-activated endothelial cells.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
HAKKERT ET AL
The anti-ELAM-1 MoAb reduced monocyte adherence to rIL-lp-pretreated endothelial cells to a similar extent as was observed for the anti-CD18 MoAb (29% ? 5%; P < .05 and 28% 2 4%; P < .05, respectively). However, the anti-ELAM-1 MoAb was less effective in inhibiting monocyte migration across rIL-1 P-stimulated endothelial cells (26% 4%). The anti-ELAM-1 MoAb had no effect on monocyte adherence to untreated or 24-hour rIL-1 ppretreated endothelial cells (data not shown). Combined use of these anti-CD18 and anti-ELAM-1 antibodies had an additive inhibitory effect (49% 2 6%; P < .01) on monocyte adherence.
Anti-VLA-4 MoAb HP113 had little effect on monocyte adherence to, as well as migration across, cytokineactivated endothelial cells (17% 2 6% and 17% f 4% inhibition, respectively). Similar results were obtained with anti-VLA-4 MoAb HP2/1 (data not shown). Anti-CD18 and anti-VLA-4 MoAbs used in combination had an additive inhibitory effect on monocyte adherence to rIL-lppretreated endothelial cells (41% f 6%; P < .01). The anti-VLA-4 MoAbs had no effect on monocyte adherence to untreated endothelial cells (data not shown).
Both rIL-1 P-induced monocyte adhesion and migration were reduced to far below baseline levels (61% 5 7%; P < .01 and 68% f 4%; P < .01, respectively) when the MoAbs against CDl8, ELAM-1, and VLA-4 were used in combination.
DISCUSSION
Leukocyte adherence to and migration across monolayers of cytokine-activated endothelial cells. Several studies have
shown that cytokine activation of endothelial cells increases the adherence of neutrophils to a much greater extent than monocyte a d h e r e n~e .~.~.~~ Although cytokine-pretreatment of endothelial cells enhanced both neutrophil and monocyte migration, clear differences were observed in the migration properties of these cells. First, neutrophil migration was to a much greater extent increased by rIL-1pactivation of endothelial cells than monocyte migration (Figs 1 and 2) . Secondly, visual evaluation of the number of migrated leukocytes under these conditions showed that neutrophils penetrated deeper into the collagen matrices than monocytes (not shown). In the present study we observed that both neutrophil and monocyte migration across monolayers of rIL-lp-stimulated endothelial cells was enhanced to a much greater extent than we have observed b e f~r e .~ The differences in our findings were due to the two types of collagen used in these studies, indicating that the migratory properties of leukocytes into the subendothelial culture matrix are directly influenced by the matrix itself.
Contribution of CD18, ELAM-1, and YLA-4 to leukocyte adherence. The adherence of nonstimulated neutrophils to endothelial cells pretreated for 4 hours with rIL-lp is in part CD18-dependent and in part CD18-independent.42'4.27 Our studies confirm the importance of ELAM-1 in neutrophil adherence to rIL-1 p-pretreated endothelial Neutrophil adherence was almost completely prevented when the anti-ELAM-1 MoAb was used in combination with the antLCD18 MoAb (Fig 1) . The anti-ELAM-1 MoAb had no effect on the adherence of neutrophils to 24-hour rIL-lp-pretreated endothelial cells, which was due to the rapid decline of ELAM-1 expression in vitro (Table   Previously , ELAM-1 has been identified as a cytokineinducible endothelial receptor for neutrophil^.^ Here, we show that the anti-ELAM-1 MoAb ENA2 also significantly blocked (29% 2 5%) monocyte adherence to rIL-lpstimulated endothelial cells (Fig 2) . Similarly, in a separate study, Leeuwenberg et ala showed that at 4°C monocyte adherence to cytokine-activated endothelium was strongly inhibited by MoAb ENA2. The finding that ELAM-1 is not only involved in neutrophil adherence to cytokine-activated endothelium but in monocyte adherence as well is in agreement with the recent observations that the carbohydrate ligand of ELAM-1, the sialated Lewis-X antigen, is expressed on both neutrophils and monocyte^.^' The inhibitory effects of the anti-ELAM-1 and anti-CD18 MoAbs on monocyte adherence were similar when used alone and additive when used in combination. However, under these latter conditions, a substantial number of monocytes still adhered to the rIL-lp-treated endothelial cells (Fig 2) . This finding indicates that additional, CD18-and ELAM-1independent mechanisms are involved in monocyte adherence to cytokine-activated endothelial cells.
Besides ELAM-1 induction, cytokines also induce the expression of VCAM-1 on endothelial cells ( Table 1 ). The leukocytic receptor for VCAM-1 is VLA-4, which also functions as a receptor for fibrone~tin.'~.'~ The anti-VLA-4 MoAb HP1/3, which potently blocks VCAM-11VLA-4 interactions without interfering in the binding to fibronectin,12 did not significantly inhibit monocyte adherence, unless used in combination with the anti-CD18 MoAb.
The reduction in monocyte adherence to rIL-1 pprestimulated endothelial cells was even more pronounced when MoAbs against CDl8, ELAM-1, and VLA-4 were combined (Fig 2) . Yet, even the combination of these three MoAbs did not completely prevent monocyte adherence to endothelial cells, indicating that other adhesive mechanisms are also involved.
Endothelial cells grown in monolayers are presumably covered with several matrix proteins. Preliminary studies, using inhibitory MoAbs against the ci chains of several VLA integrins, indicate that this "remaining" monocyte adherence is at least in part mediated by the binding of monocytes to fibronectin and laminin through the specific receptors for extracellular matrix protein~'~ VLAJ and VLA-6 (B.C. Hakkert, T.W. Kuijpers, unpublished results).
Contribution of CDl8, ELAM-1, and VZA-4 to leukocyte migration. We4 and others3' have shown that anti-CD18 MoAbs reduce neutrophil migration across monolayers of cytokine-activated endothelial cells to baseline levels. We show here that the anti-ELAM-1 MoAb is much less effective in inhibiting the rIL-1p-induced neutrophil migra-1).
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From tion than the antLCD18 MoAb (Fig l) .* Taken together, our data strongly indicate that neutrophil adherence largely proceeds in a CD184ndependent way, subsequently switching to a CD18-dependent mechanism of migration. In a way, this concept perfectly matches with a recent report by Lawrence et a1: ' who noted that under flow conditions the neutrophil adherence to cytokine-activated endothelial cells was completely CD18-independent, whereas migration was strongly reduced by anti-CD18 MoAbs. The investigators suggested that CDWindependent mechanisms function to initially "catch" the circulating phagocyte. In line with this idea, we recently found that neutrophil contact with ELAM-1 on rIL-lp-stimulated endothelial cells leads to enhanced adherence through CD18."
Monocyte migration across cytokine-pretreated endothelial cell monolayers was also strongly reduced by the anti-CD18 MoAb, whereas MoAbs against ELAM-1 and VLA-4 had no significant effect (Fig 2) . These results are in *While this report was under review, a study by Luscinkas et al" was published in which greater than 90% inhibition of neutrophil migration across 4-hour rlL-1 P-activated endothelial cells by MoAb H18/7 against ELAM-1 is described.
amrdance with the findings that neutrophils and monocytes from patients with a genetic defect in the p2 integrin CD18 (leukocyte adhesion deficiency [LAD] patients) fail to accumulate at idammatory sites? In contrast, the migration of lymphocytes from LAD patients is essentially normal, and it has been suggested that VCAM-l/VLA-4 interactions play an important role in the recruitment of MoAbs against VCAM-1 or VLA-4 only affected cytokine-induced monocyte adherence" and migration (our study) when used in combination with MoAbs against CD18, indicating that the VCAM-l/VLA-4 interactions alone are not sufficient, either for monocyte adherence or for migration.
We have shown that ELAM-1 is not only involved in neutrophil adherence to rIL-1 P-prestimulated endothelial cells, but in monocyte adherence as well. The reduction in monocyte adherence was most pronounced when MoAbs against CD18, ELAM-1, and VLA-4 were used in combination. Although both neutrophil and monocyte adherence to cytokine-activated endothelial cells is mediated by CD18-independent and (to a lesser extent) by CD18-dependent mechanisms, migration across monolayers of cytokine-activated endothelial cells is predominantly CD18-dependent.
Conclusions.
